Policy & Regulation
Invivyd's VYD222 shows neutralising activity against dominant SARS-CoV-2 variants
14 June 2024 -

Biopharmaceutical company Invivyd Inc (Nasdaq:IVVD) on Friday reported data showing continued in vitro activity of its mAb candidate, VYD222 (pemivibart), against prevalent SARS-CoV-2 variants, including KP.1.1 FLiRT and KP.3.

These variants are projected to become dominant strains.

The data aligns with independent research suggesting VYD222's effectiveness against these variants.

Invivyd's next mAb candidate, VYD2311, also shows promise against these strains.